Drug Trial Radar · NCT04781816
Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Apr 1, 2021
Primary completion
May 25, 2023
Study completion Jun 26, 2023
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: * Assess the efficacy of SAR443122 in cutaneous lupus erythematosus (CLE) Secondary Objectives: * Assess the effect of SAR443122 on the physician's global assessment of disease activity (PhysGA - disease activity) * Assess the effect of SAR443122 on CLE induced itch and overall pain * Assess the effect of SAR443122 on the proportion of disease activity responders compared to placebo * Assess the effect of SAR443122 on the CLASI components score * Assess the effect of SAR443122 on the Investigator's global assessment for CLE (IGA-CLE) * Assess oral cavities for patients with oral lesions * Assess the disease specific quality of life (QoL) * Assess the safety and tolerability of SAR443122 in patients with CLE * Assess the pharmacokinetics (PK) exposure of SAR443122 in patients with CLE
Conditions
- Cutaneous Lupus Erythematosus
Interventions
SAR443122Drug
Pharmaceutical form: Capsule Route of administration: Oral
PlaceboDrug
Pharmaceutical form: Capsule Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Cutaneous Erythematosus Disease Area and Severity Index - Activity (CLASI-A) Sub-Score at Week 12Time frame: Baseline (Day 1) and Week 12
Locations
50 sites in 15 countries. Site status is shown where the registry gives one.
GNP Research Site Number : 8400008
Cooper City, Florida
DJL Clinical Research, PLLC Site Number : 8400003
Charlotte, North Carolina
ClinOhio Research Services Site Number : 8400007
Columbus, Ohio
Prolato Clinical Research Center Site Number : 8400010
Houston, Texas
Investigational Site Number : 0320005
Mendoza, Argentina
Investigational Site Number : 0320002
CABA, Buenos Aires, Argentina
Investigational Site Number : 0320003
CABA, Buenos Aires, Argentina
Investigational Site Number : 0320001
CABA, Buenos Aires, Argentina
Investigational Site Number : 0320004
Rosario, Santa Fe Province, Argentina
Investigational Site Number : 0360001
Camberwell, Victoria, Australia
Investigational Site Number : 0360002
East Melbourne, Victoria, Australia
Investigational Site Number : 1240001
London, Ontario, Canada
Investigational Site Number : 1240005
Toronto, Ontario, Canada
Investigational Site Number : 1240002
Sherbrooke, Quebec, Canada
Investigational Site Number : 1520009
Valdivia, Los Ríos Region, Chile
Investigational Site Number : 1520006
Osorno, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520007
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520003
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 2030002
Brno, Czechia
Investigational Site Number : 2030004
Náchod, Czechia
Investigational Site Number : 2030006
Pardubice, Czechia
Investigational Site Number : 2030005
Prague, Czechia
Investigational Site Number : 3480001
Budapest, Hungary
Investigational Site Number : 3480002
Szeged, Hungary
Investigational Site Number : 3560002
Chandigarh, India
Investigational Site Number : 3560003
Nagpur, India
Investigational Site Number : 3560004
Nashik, India
Investigational Site Number : 3800001
Genova, Italy
Investigational Site Number : 3800002
Milan, Italy
Investigational Site Number : 4840003
Benito Juárez, Mexico
Investigational Site Number : 4840004
Chihuahua City, Mexico
Investigational Site Number : 4840001
Monterrey, Nuevo León, Mexico
Investigational Site Number : 4840002
Veracruz, Mexico
Investigational Site Number : 6160006
Krakow, Lesser Poland Voivodeship, Poland
Investigational Site Number : 6160004
Lublin, Lublin Voivodeship, Poland
Investigational Site Number : 6160007
Katowice, Silesian Voivodeship, Poland
Investigational Site Number : 6430004
Krasnodar, Russia
Investigational Site Number : 6430005
Moscow, Russia
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.